Credit: BeiGene
October 28, 2024 12:07 PM EDTUpdated 02:38 PM
China
Pharma

BeiGene ex­ec­u­tive re­port­ed­ly un­der in­ves­ti­ga­tion in Chi­na

Max Bayer

Pharma Reporter

Eva Yin, the chief com­mer­cial of­fi­cer for Greater Chi­na at BeiGene, is re­port­ed­ly un­der in­ves­ti­ga­tion by lo­cal au­thor­i­ties for al­leged ties to an in­sur­ance fraud …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ab­b­Vie makes $1.4B ac­qui­si­tion of Alzheimer's biotech

For­mer Seagen CEO David Ep­stein to lead new biotech with VEGF bi­func­tion­al an­ti­body

No­var­tis pays Monte Rosa $150M for Phase 1 drug in lat­est en­dorse­ment of mol­e­c­u­lar glues

Fog­Phar­ma re­brands as Para­bilis Med­i­cines, as CEO Math­ai Mam­men high­lights next drugs

Synaf­fix, in­dus­try's ADC part­ner of choice, spins out a start­up pipeline

Bio­gen's full Ph2 da­ta for IgA nephropa­thy drug; Sanofi in­vests in obe­si­ty biotech

A service from the Financial Times